Robin Shane Readnour, Director at AN2 Therapeutics, Inc. (ANTX), bought 200,000 shares at $1.04 ($213K) on 2024-11-19, disclosed to the SEC on 2024-11-21.
Open-market purchase of $213k ANTX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.03 | 75,000 | $77K | 36.3% |
| 2 | $1.04 | 75,000 | $78K | 36.6% |
| 3 | $1.15 | 25,000 | $29K | 13.5% |
| 4 | $1.16 | 25,000 | $29K | 13.6% |
| Total | $1.06 avg | 200,000 | $213K | 100% |
| Filing → |
| ANTX | SELL | 2026-08-19 | $213K | — | Filing → |
| ANTX | BUY | 2024-12-10 | $79K | — | Filing → |
| ANTX | BUY | 2024-11-27 | $53K | — | Filing → |